Post hoc analysis of a phase 3 trial in 67 participants with very severe hypertriglyceridaemia and prior acute pancreatitis: recurrent pancreatitis occurred in 2 of 45 with plozasiran vs 5 of 22 with placebo (HR 0.17).
Secondary analysisn = 67
Loomba et al. Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia-Results of a Post Hoc Analysis of the Phase 3 PALISADE Study